Soligenix

339 articles with Soligenix

• Soligenix Announces Recent Accomplishments And Third Quarter 2020 Financial Results

  11/12/2020

  Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced its recent accomplishments and financial results for the quarter ended September 30, 2020.

• Soligenix Invited to Present at Upcoming Virtual Investor Conferences

  11/10/2020

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber,

• Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma

  10/22/2020

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that continued optional treatment with SGX301 (synthetic hypericin) across all lesions during the compassionate use, safety portion of the trial (Cycle 3)

• Soligenix to Present at the BIO Investor Forum

  10/8/2020

   Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), announced today that its President and Chief Executive Officer, Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the BIO Investor Forum, held virtually October 13-15, 2020.

• Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens

  9/15/2020

  - Protein antigen stability after lyophilization demonstrated - Key analytical assays identified

• Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine

  9/10/2020

  Preclinical data supports potential for: - Broadly applicable vaccine (young, elderly, immunocompromised) - Rapid onset of immunogenicity within 7 days of the first dose - Thermostabilized vaccine (ambient storage/shipping with no need for cold chain) - Multivalent vaccine formulation, if needed - Readily adaptable vaccine for seasonal vaccination use, if needed   [10-September-2020]

• Soligenix Invited to Present at Upcoming Virtual Investor Conferences - Sep 09, 2020

  9/9/2020

  Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the upcoming virtual investor conferences below.

• Soligenix Announces Investor Webcast Event: Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine

  9/3/2020

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be

• Soligenix to Present at the LD Micro Conference

  8/27/2020

  Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that its Senior Vice President and Chief Financial Officer, Jonathan Guarino, will deliver a corporate presentation at the LD Micro Conference, held virtually September 1-4, 2020.

• Soligenix Announces Recent Accomplishments And Second Quarter 2020 Financial Results

  8/14/2020

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2020 . Christopher J.

• Soligenix Announces Publication of Positive Pre-clinical Results for a Novel COVID-19 Vaccine

  7/28/2020

  - Rapid Immune Responses Demonstrated with CoVaccine HT™ Adjuvant in a Prototype Vaccine - Key Attributes including Generation of Neutralizing Antibodies, Th1 Antibody and Cell Mediated Responses Established

• Soligenix Issues Corporate Update - Highlights Important Catalysts for Second Half of 2020

  7/20/2020

  Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.

• Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis

  6/24/2020

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in it

• Soligenix to Join Russell Microcap® Index

  6/22/2020

  Soligenix, Inc. announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29th, according to a final list of additions posted June 15th.

• Soligenix to Present at the MedInvest Infectious Disease and Immunology Investor Conference

  6/9/2020

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Senior Vice President and Chief Scientific Officer, Oreola Donini, PhD, will deliver a presenta

• Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results

  5/15/2020

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2020 . Christopher J. Sch

• Soligenix Announces Publication of Correlates of Immune Protection for the RiVax® Ricin Toxin Vaccine

  5/11/2020

  Soligenix, Inc. announced publication of immunogenicity studies for RiVax® identifying novel correlates of immune protection to facilitate potential approval under the United States Food and Drug Administration "Animal Rule." The article, titled "A Multivariate Model Combining Endpoint and Epitope-specific Antibody Responses as a Correlate of Protection to Ricin Toxin," has been submitted to the peer-reviewed medical journal Vaccine and a preprint is available here.

• Soligenix Receives $840,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

  5/7/2020

  Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that it has received approximately $840,000, net of transaction costs, in non-dilutive financing via the state of New Jersey's Technology Business Tax Certificate Transfer Program.

• Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma

  4/30/2020

  Reinforces positive SGX301 primary endpoint treatment response demonstrating statistical significance after 6 weeks of therapy

• Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals

  4/16/2020

   Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it ha